Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.
Identifieur interne : 003939 ( PubMed/Corpus ); précédent : 003938; suivant : 003940Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.
Auteurs : Gerald F. Watts ; Samuel Gidding ; Anthony S. Wierzbicki ; Peter P. Toth ; Rodrigo Alonso ; W Virgil Brown ; Eric Bruckert ; Joep Defesche ; Khoo Kah Lin ; Michael Livingston ; Pedro Mata ; Klaus G. Parhofer ; Frederick J. Raal ; Raul D. Santos ; Eric J G. Sijbrands ; William G. Simpson ; David R. Sullivan ; Andrey V. Susekov ; Brian Tomlinson ; Albert Wiegman ; Shizuya Yamashita ; John J P. KasteleinSource :
- International journal of cardiology [ 1874-1754 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anticholesteremic Agents.
- diagnosis : Hyperlipoproteinemia Type II.
- methods : Patient Care.
- standards : Foundations, Patient Care, Practice Guidelines as Topic.
- therapy : Hyperlipoproteinemia Type II.
- Humans, Internationality.
Abstract
Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) cholesterol and causes premature coronary heart disease. There are at least 20 million people with FH worldwide, but the majority remain undetected and current treatment is often suboptimal. To address this major gap in coronary prevention we present, from an international perspective, consensus-based guidance on the care of FH. The guidance was generated from seminars and workshops held at an international symposium. The recommendations focus on the detection, diagnosis, assessment and management of FH in adults and children, and set guidelines for clinical purposes. They also refer to best practice for cascade screening and risk notifying and testing families for FH, including use of genetic testing. Guidance on treatment is based on risk stratification, management of non-cholesterol risk factors, and safe and effective use of LDL lowering therapies. Recommendations are given on lipoprotein apheresis. The use of emerging therapies for FH is also foreshadowed. This international guidance acknowledges evidence gaps, but aims to make the best use of contemporary practice and technology to achieve the best outcomes for the care of FH. It should accordingly be employed to inform clinical judgement and be adjusted for country-specific and local health care needs and resources.
DOI: 10.1016/j.ijcard.2013.11.025
PubMed: 24418289
Links to Exploration step
pubmed:24418289Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.</title><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation><nlm:affiliation>Cardiometabolic Service, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Australia. Electronic address: gerald.watts@uwa.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Gidding, Samuel" sort="Gidding, Samuel" uniqKey="Gidding S" first="Samuel" last="Gidding">Samuel Gidding</name><affiliation><nlm:affiliation>Cardiology Division, Nemours Cardiac Center, A. I. duPont Hospital for Children, Wilmington, DE, USA; Jefferson Medical College, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wierzbicki, Anthony S" sort="Wierzbicki, Anthony S" uniqKey="Wierzbicki A" first="Anthony S" last="Wierzbicki">Anthony S. Wierzbicki</name><affiliation><nlm:affiliation>Department of Metabolic Medicine and Chemical Pathology, Guy's & St Thomas Hospitals, NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Toth, Peter P" sort="Toth, Peter P" uniqKey="Toth P" first="Peter P" last="Toth">Peter P. Toth</name><affiliation><nlm:affiliation>CGH Medical Centre, Sterling Illinois, University of Illinois College of Medicine, Peoria, USA; Illinois Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Alonso, Rodrigo" sort="Alonso, Rodrigo" uniqKey="Alonso R" first="Rodrigo" last="Alonso">Rodrigo Alonso</name><affiliation><nlm:affiliation>Lipid Clinic, Department of Internal Medicine, Fundacion Jimenez Diaz, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, W Virgil" sort="Brown, W Virgil" uniqKey="Brown W" first="W Virgil" last="Brown">W Virgil Brown</name><affiliation><nlm:affiliation>Emory University School of Medicine, Emory University, Atlanta, GA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation><nlm:affiliation>Department of Endocrinology and Prevention of Cardiovascular Disease, Hôpital Pitié-Salpêtrière, University of Paris VI, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Defesche, Joep" sort="Defesche, Joep" uniqKey="Defesche J" first="Joep" last="Defesche">Joep Defesche</name><affiliation><nlm:affiliation>Laboratory for Experimental Vascular Medicine, Section of Molecular Diagnostics, Academic Medical Centre, University of Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Khoo Kah" sort="Lin, Khoo Kah" uniqKey="Lin K" first="Khoo Kah" last="Lin">Khoo Kah Lin</name><affiliation><nlm:affiliation>Pontai Medical Centre, Heart Foundation of Malaysia, Kuala Lumpur, Malaysia.</nlm:affiliation></affiliation></author><author><name sortKey="Livingston, Michael" sort="Livingston, Michael" uniqKey="Livingston M" first="Michael" last="Livingston">Michael Livingston</name><affiliation><nlm:affiliation>The International FH Foundation, St Andrews Court, Thame, Oxfordshire, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Mata, Pedro" sort="Mata, Pedro" uniqKey="Mata P" first="Pedro" last="Mata">Pedro Mata</name><affiliation><nlm:affiliation>Fundacion Hipercolesterolemia Familiar, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Parhofer, Klaus G" sort="Parhofer, Klaus G" uniqKey="Parhofer K" first="Klaus G" last="Parhofer">Klaus G. Parhofer</name><affiliation><nlm:affiliation>Medical Department 2, Division of Metabolism and Endocrinology, Ludwig-Maximilians-University of Munich, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Raal, Frederick J" sort="Raal, Frederick J" uniqKey="Raal F" first="Frederick J" last="Raal">Frederick J. Raal</name><affiliation><nlm:affiliation>Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Santos, Raul D" sort="Santos, Raul D" uniqKey="Santos R" first="Raul D" last="Santos">Raul D. Santos</name><affiliation><nlm:affiliation>Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School, University of Sao Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Sijbrands, Eric J G" sort="Sijbrands, Eric J G" uniqKey="Sijbrands E" first="Eric J G" last="Sijbrands">Eric J G. Sijbrands</name><affiliation><nlm:affiliation>Section of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Simpson, William G" sort="Simpson, William G" uniqKey="Simpson W" first="William G" last="Simpson">William G. Simpson</name><affiliation><nlm:affiliation>Department of Clinical Biochemistry, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, Scotland, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Sullivan, David R" sort="Sullivan, David R" uniqKey="Sullivan D" first="David R" last="Sullivan">David R. Sullivan</name><affiliation><nlm:affiliation>Lipid Clinic and Department of Biochemistry, Royal Prince Alfred Hospital, University of Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Susekov, Andrey V" sort="Susekov, Andrey V" uniqKey="Susekov A" first="Andrey V" last="Susekov">Andrey V. Susekov</name><affiliation><nlm:affiliation>Laboratory of Clinical Lipidology, Department of Atherosclerosis, Cardiology Research Complex, Ministry of Health of Russian Federation, Moscow, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Tomlinson, Brian" sort="Tomlinson, Brian" uniqKey="Tomlinson B" first="Brian" last="Tomlinson">Brian Tomlinson</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wiegman, Albert" sort="Wiegman, Albert" uniqKey="Wiegman A" first="Albert" last="Wiegman">Albert Wiegman</name><affiliation><nlm:affiliation>Department of Paediatrics, Academic Medical Centre, University of Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Yamashita, Shizuya" sort="Yamashita, Shizuya" uniqKey="Yamashita S" first="Shizuya" last="Yamashita">Shizuya Yamashita</name><affiliation><nlm:affiliation>Department of Community Medicine, Osaka University Graduate School of Medicine, Osaka University, Japan; Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka University, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Kastelein, John J P" sort="Kastelein, John J P" uniqKey="Kastelein J" first="John J P" last="Kastelein">John J P. Kastelein</name><affiliation><nlm:affiliation>Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24418289</idno><idno type="pmid">24418289</idno><idno type="doi">10.1016/j.ijcard.2013.11.025</idno><idno type="wicri:Area/PubMed/Corpus">003939</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003939</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.</title><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation><nlm:affiliation>Cardiometabolic Service, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Australia. Electronic address: gerald.watts@uwa.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Gidding, Samuel" sort="Gidding, Samuel" uniqKey="Gidding S" first="Samuel" last="Gidding">Samuel Gidding</name><affiliation><nlm:affiliation>Cardiology Division, Nemours Cardiac Center, A. I. duPont Hospital for Children, Wilmington, DE, USA; Jefferson Medical College, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wierzbicki, Anthony S" sort="Wierzbicki, Anthony S" uniqKey="Wierzbicki A" first="Anthony S" last="Wierzbicki">Anthony S. Wierzbicki</name><affiliation><nlm:affiliation>Department of Metabolic Medicine and Chemical Pathology, Guy's & St Thomas Hospitals, NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Toth, Peter P" sort="Toth, Peter P" uniqKey="Toth P" first="Peter P" last="Toth">Peter P. Toth</name><affiliation><nlm:affiliation>CGH Medical Centre, Sterling Illinois, University of Illinois College of Medicine, Peoria, USA; Illinois Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Alonso, Rodrigo" sort="Alonso, Rodrigo" uniqKey="Alonso R" first="Rodrigo" last="Alonso">Rodrigo Alonso</name><affiliation><nlm:affiliation>Lipid Clinic, Department of Internal Medicine, Fundacion Jimenez Diaz, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, W Virgil" sort="Brown, W Virgil" uniqKey="Brown W" first="W Virgil" last="Brown">W Virgil Brown</name><affiliation><nlm:affiliation>Emory University School of Medicine, Emory University, Atlanta, GA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation><nlm:affiliation>Department of Endocrinology and Prevention of Cardiovascular Disease, Hôpital Pitié-Salpêtrière, University of Paris VI, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Defesche, Joep" sort="Defesche, Joep" uniqKey="Defesche J" first="Joep" last="Defesche">Joep Defesche</name><affiliation><nlm:affiliation>Laboratory for Experimental Vascular Medicine, Section of Molecular Diagnostics, Academic Medical Centre, University of Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Khoo Kah" sort="Lin, Khoo Kah" uniqKey="Lin K" first="Khoo Kah" last="Lin">Khoo Kah Lin</name><affiliation><nlm:affiliation>Pontai Medical Centre, Heart Foundation of Malaysia, Kuala Lumpur, Malaysia.</nlm:affiliation></affiliation></author><author><name sortKey="Livingston, Michael" sort="Livingston, Michael" uniqKey="Livingston M" first="Michael" last="Livingston">Michael Livingston</name><affiliation><nlm:affiliation>The International FH Foundation, St Andrews Court, Thame, Oxfordshire, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Mata, Pedro" sort="Mata, Pedro" uniqKey="Mata P" first="Pedro" last="Mata">Pedro Mata</name><affiliation><nlm:affiliation>Fundacion Hipercolesterolemia Familiar, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Parhofer, Klaus G" sort="Parhofer, Klaus G" uniqKey="Parhofer K" first="Klaus G" last="Parhofer">Klaus G. Parhofer</name><affiliation><nlm:affiliation>Medical Department 2, Division of Metabolism and Endocrinology, Ludwig-Maximilians-University of Munich, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Raal, Frederick J" sort="Raal, Frederick J" uniqKey="Raal F" first="Frederick J" last="Raal">Frederick J. Raal</name><affiliation><nlm:affiliation>Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Santos, Raul D" sort="Santos, Raul D" uniqKey="Santos R" first="Raul D" last="Santos">Raul D. Santos</name><affiliation><nlm:affiliation>Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School, University of Sao Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Sijbrands, Eric J G" sort="Sijbrands, Eric J G" uniqKey="Sijbrands E" first="Eric J G" last="Sijbrands">Eric J G. Sijbrands</name><affiliation><nlm:affiliation>Section of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Simpson, William G" sort="Simpson, William G" uniqKey="Simpson W" first="William G" last="Simpson">William G. Simpson</name><affiliation><nlm:affiliation>Department of Clinical Biochemistry, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, Scotland, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Sullivan, David R" sort="Sullivan, David R" uniqKey="Sullivan D" first="David R" last="Sullivan">David R. Sullivan</name><affiliation><nlm:affiliation>Lipid Clinic and Department of Biochemistry, Royal Prince Alfred Hospital, University of Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Susekov, Andrey V" sort="Susekov, Andrey V" uniqKey="Susekov A" first="Andrey V" last="Susekov">Andrey V. Susekov</name><affiliation><nlm:affiliation>Laboratory of Clinical Lipidology, Department of Atherosclerosis, Cardiology Research Complex, Ministry of Health of Russian Federation, Moscow, Russia.</nlm:affiliation></affiliation></author><author><name sortKey="Tomlinson, Brian" sort="Tomlinson, Brian" uniqKey="Tomlinson B" first="Brian" last="Tomlinson">Brian Tomlinson</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wiegman, Albert" sort="Wiegman, Albert" uniqKey="Wiegman A" first="Albert" last="Wiegman">Albert Wiegman</name><affiliation><nlm:affiliation>Department of Paediatrics, Academic Medical Centre, University of Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Yamashita, Shizuya" sort="Yamashita, Shizuya" uniqKey="Yamashita S" first="Shizuya" last="Yamashita">Shizuya Yamashita</name><affiliation><nlm:affiliation>Department of Community Medicine, Osaka University Graduate School of Medicine, Osaka University, Japan; Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka University, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Kastelein, John J P" sort="Kastelein, John J P" uniqKey="Kastelein J" first="John J P" last="Kastelein">John J P. Kastelein</name><affiliation><nlm:affiliation>Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International journal of cardiology</title><idno type="eISSN">1874-1754</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticholesteremic Agents (therapeutic use)</term><term>Foundations (standards)</term><term>Humans</term><term>Hyperlipoproteinemia Type II (diagnosis)</term><term>Hyperlipoproteinemia Type II (therapy)</term><term>Internationality</term><term>Patient Care (methods)</term><term>Patient Care (standards)</term><term>Practice Guidelines as Topic (standards)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticholesteremic Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hyperlipoproteinemia Type II</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Patient Care</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Foundations</term><term>Patient Care</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hyperlipoproteinemia Type II</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Internationality</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) cholesterol and causes premature coronary heart disease. There are at least 20 million people with FH worldwide, but the majority remain undetected and current treatment is often suboptimal. To address this major gap in coronary prevention we present, from an international perspective, consensus-based guidance on the care of FH. The guidance was generated from seminars and workshops held at an international symposium. The recommendations focus on the detection, diagnosis, assessment and management of FH in adults and children, and set guidelines for clinical purposes. They also refer to best practice for cascade screening and risk notifying and testing families for FH, including use of genetic testing. Guidance on treatment is based on risk stratification, management of non-cholesterol risk factors, and safe and effective use of LDL lowering therapies. Recommendations are given on lipoprotein apheresis. The use of emerging therapies for FH is also foreshadowed. This international guidance acknowledges evidence gaps, but aims to make the best use of contemporary practice and technology to achieve the best outcomes for the care of FH. It should accordingly be employed to inform clinical judgement and be adjusted for country-specific and local health care needs and resources.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24418289</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>27</Day></DateCreated><DateCompleted><Year>2014</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2014</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>171</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int. J. Cardiol.</ISOAbbreviation></Journal><ArticleTitle>Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.</ArticleTitle><Pagination><MedlinePgn>309-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2013.11.025</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(13)01997-9</ELocationID><Abstract><AbstractText>Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) cholesterol and causes premature coronary heart disease. There are at least 20 million people with FH worldwide, but the majority remain undetected and current treatment is often suboptimal. To address this major gap in coronary prevention we present, from an international perspective, consensus-based guidance on the care of FH. The guidance was generated from seminars and workshops held at an international symposium. The recommendations focus on the detection, diagnosis, assessment and management of FH in adults and children, and set guidelines for clinical purposes. They also refer to best practice for cascade screening and risk notifying and testing families for FH, including use of genetic testing. Guidance on treatment is based on risk stratification, management of non-cholesterol risk factors, and safe and effective use of LDL lowering therapies. Recommendations are given on lipoprotein apheresis. The use of emerging therapies for FH is also foreshadowed. This international guidance acknowledges evidence gaps, but aims to make the best use of contemporary practice and technology to achieve the best outcomes for the care of FH. It should accordingly be employed to inform clinical judgement and be adjusted for country-specific and local health care needs and resources.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Gerald F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Cardiometabolic Service, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Australia. Electronic address: gerald.watts@uwa.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gidding</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Division, Nemours Cardiac Center, A. I. duPont Hospital for Children, Wilmington, DE, USA; Jefferson Medical College, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wierzbicki</LastName><ForeName>Anthony S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Metabolic Medicine and Chemical Pathology, Guy's & St Thomas Hospitals, NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>CGH Medical Centre, Sterling Illinois, University of Illinois College of Medicine, Peoria, USA; Illinois Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lipid Clinic, Department of Internal Medicine, Fundacion Jimenez Diaz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>W Virgil</ForeName><Initials>WV</Initials><AffiliationInfo><Affiliation>Emory University School of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruckert</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Prevention of Cardiovascular Disease, Hôpital Pitié-Salpêtrière, University of Paris VI, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defesche</LastName><ForeName>Joep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Experimental Vascular Medicine, Section of Molecular Diagnostics, Academic Medical Centre, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Khoo Kah</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Pontai Medical Centre, Heart Foundation of Malaysia, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The International FH Foundation, St Andrews Court, Thame, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mata</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fundacion Hipercolesterolemia Familiar, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parhofer</LastName><ForeName>Klaus G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Medical Department 2, Division of Metabolism and Endocrinology, Ludwig-Maximilians-University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raal</LastName><ForeName>Frederick J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Raul D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School, University of Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sijbrands</LastName><ForeName>Eric J G</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Section of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>William G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, Scotland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Lipid Clinic and Department of Biochemistry, Royal Prince Alfred Hospital, University of Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Susekov</LastName><ForeName>Andrey V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Lipidology, Department of Atherosclerosis, Cardiology Research Complex, Ministry of Health of Russian Federation, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiegman</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Academic Medical Centre, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Shizuya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, Osaka University Graduate School of Medicine, Osaka University, Japan; Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastelein</LastName><ForeName>John J P</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Atheroscler Thromb. 2014;21(4):366-7</RefSource><PMID Version="1">24573014</PMID></CommentsCorrections><CommentsCorrections RefType="ReprintIn"><RefSource>J Atheroscler Thromb. 2014;21(4):368-74</RefSource><PMID Version="1">24892180</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005582" MajorTopicYN="N">Foundations</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006938" MajorTopicYN="N">Hyperlipoproteinemia Type II</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="Y">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005791" MajorTopicYN="N">Patient Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Assessment</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Familial hypercholesterolaemia</Keyword><Keyword MajorTopicYN="N">Models of care</Keyword><Keyword MajorTopicYN="N">Screening</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24418289</ArticleId><ArticleId IdType="pii">S0167-5273(13)01997-9</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2013.11.025</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24418289
|texte= Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24418289" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |